News | August 26, 2021
Strong show in domestic formulations business by Indian pharma in Q1FY22: Ind-Ra
Domestic business was up 41.9% YoY and 27.7% QoQ
Domestic business was up 41.9% YoY and 27.7% QoQ
BD worked with JCI to create a Gold Standard benchmarked safety program called Preventing Risks of Infections and Medication Errors in IV Therapy (PRIME)
CDSCO gives the green signal as HGCO19 was safe, tolerable and immunogenic in the participants of the study
The acquisition was expected to be completed in eight weeks, and it would have provided it with a foothold in the US $ 48 billion global animal health market
The group, known as the HIV Obstruction by Programmed Epigenetics (HOPE) Collaboratory, will be led by researchers at Gladstone Institutes, Scripps Research Florida, and Weill Cornell Medicine. Their approach, which aims to both silence and permanently remove HIV from the body, takes advantage of knowledge about how other viruses have become naturally inactivated over time.
Price erosion, weak demand for acute portfolio and low ANDA approvals in the US weighed on the performance of Indian pharma in Q1FY22. However, the scenario is expected to change in H2FY22 when new approvals and inspections resume
The company expects a potential sales turnover of Rs.350-500 crores at 100 % capacity utilization
India’s dependency on China for pharma intermediates can change if there is a proper coordination between educational institutes, research institutes and pharma manufacturers
_256_384.jpg)
The focus of this year’s challenge is to find solutions within Covid management and treatment of cardiovascular, renal, neuro, cancer and lung diseases
Domestic market and developing countries will need doses of Indian vaccines
Subscribe To Our Newsletter & Stay Updated
